GlaxoSmithKline plc (GSK) Insider Emma Walmsley Purchases 8 Shares

Share on StockTwits

GlaxoSmithKline plc (LON:GSK) insider Emma Walmsley bought 8 shares of GlaxoSmithKline stock in a transaction on Thursday, January 10th. The stock was acquired at an average price of GBX 1,524 ($19.91) per share, with a total value of £121.92 ($159.31).

Emma Walmsley also recently made the following trade(s):

  • On Tuesday, December 11th, Emma Walmsley bought 8 shares of GlaxoSmithKline stock. The stock was acquired at an average price of GBX 1,494 ($19.52) per share, with a total value of £119.52 ($156.17).

Shares of GSK stock opened at GBX 1,507.80 ($19.70) on Monday. GlaxoSmithKline plc has a 1 year low of GBX 1,235.20 ($16.14) and a 1 year high of GBX 1,724.50 ($22.53).

The business also recently announced a dividend, which was paid on Thursday, January 10th. Investors of record on Thursday, November 15th were given a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.26%. The ex-dividend date of this dividend was Thursday, November 15th.

A number of equities analysts have recently commented on GSK shares. Liberum Capital reissued a “hold” rating on shares of GlaxoSmithKline in a research report on Tuesday, December 4th. Deutsche Bank reissued a “hold” rating on shares of GlaxoSmithKline in a research report on Monday. Credit Suisse Group set a GBX 1,600 ($20.91) price target on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research report on Tuesday, December 4th. Bank of America set a GBX 1,635 ($21.36) price target on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research report on Friday, December 14th. Finally, Kepler Capital Markets reissued a “hold” rating on shares of GlaxoSmithKline in a research report on Tuesday, December 4th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company’s stock. GlaxoSmithKline currently has an average rating of “Hold” and a consensus target price of GBX 1,530.34 ($20.00).

ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline plc (GSK) Insider Emma Walmsley Purchases 8 Shares” was first published by Week Herald and is owned by of Week Herald. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://weekherald.com/2019/01/14/glaxosmithkline-plc-gsk-insider-emma-walmsley-purchases-8-shares.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: Why do companies issue stock splits?

Insider Buying and Selling by Quarter for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply